In the current study, EOC patients with tumors overexpressing p-Akt had shorter PFS and OS, and higher rates of cancer death, which indicated that elevated p-Akt expression was an unfavorable tumor biomarker of long-term survival. The gene discussed is AKT1; the disease is cancer.